Navigation Links
Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
Date:4/20/2009

- Findings Demonstrate Survival Benefit with Picoplatin as Second-Line Therapy for Small Cell Lung Cancer -

SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that results of its Phase 2 clinical trial of picoplatin in patients with recurrent small cell lung cancer (SCLC) were published in the April 20, 2009, print issue of the Journal of Clinical Oncology(1). Picoplatin demonstrated a survival benefit in this open-label, multi-center Phase 2 trial of SCLC patients who failed prior platinum-containing first-line chemotherapy or who progressed within six months of first-line therapy. The median overall survival was 27 weeks and the median one-year survival rate was 17.6 percent in this patient population of mostly platinum-refractory and -resistant patients.

Poniard is currently evaluating the efficacy and safety of picoplatin in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) SCLC trial, which is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009.

SCLC is the most aggressive lung cancer and tends to be widely disseminated by the time of diagnosis. The prognosis for patients with SCLC that has progressed despite chemotherapy is exceedingly poor regardless of stage. Effective second-line treatment for SCLC is a major unmet need. There is no standard chemotherapy for second-line platinum-refractory or -resistant SCLC.

"New treatments are desperately needed for patients with platinum-resistant and -refractory small cell lung cancer due
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... Cincinnati, Ohio (PRWEB) August 01, 2014 ... in-home care for seniors, is honored to be recognized as ... prestigious award is given to home care providers who rank ... satisfaction categories, based on monthly satisfaction interviews conducted by Home ... recognize the leading home care businesses, the best of the ...
(Date:8/1/2014)... In recent years, minimally invasive aesthetic injectable procedures have ... women are seeking age-defying treatments. As Botulinum toxin ... a growing number of nonaesthetic health professionals have emerged ... Small, MD and Henry M. Spinelli, MD from the ... and Kathleen M. Kelly, MD from Columbia University in ...
(Date:8/1/2014)... 2014 CapsCanada, a leading provider ... a new K-CAPS® (HPMC capsules) manufacturing facility in ... plans last year while experiencing growing global demand ... Manager, “KCAPS® are currently sold in more than ... “Compared to other HPMC capsules, K-CAPS® have exceptional ...
(Date:8/1/2014)... MA (PRWEB) August 01, 2014 For ... even when memory is still within the normal range, ... warning signs of future decline. This merits a closer ... in the August 2014 Harvard Men's Health Watch ... that if they forget where their keys are they ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
... Four-legged heroes -- cats, too -- are maintaining the veterinary ... most of America,s blood donors, JJ and Logan are unaware ... saved. , But over a three-year period, the two healthy ... numerous canine patients survive surgeries and illnesses to play "fetch" ...
... Colo., April 18 Mesa Laboratories,Inc., (Nasdaq: MLAB ... will participate in a Health-Care Trade Policy Mission led ... selected as one of 15 companies,to accompany Under Secretary ... purpose of the mission is to provide a forum ...
... ROSEVILLE, Calif., April 18 CoolTouch Inc., ... introduction,of their new CoolBlue Duet(TM) laser lipolysis suction ... CoolLipo(TM) 1320 laser system.,Using a standard liposuction cannula, ... in one action, which dramatically reduces,the time of ...
... Supermarket,Company is alerting customers to a voluntary recall by Chang ... a sell by date of April 19,2008 and a UPC ... recalled because of the possible presence of,Listeria bacteria. Contamination with ... public health., Upon being notified of the recall, Stop ...
... April 17 The state,s Life Sciences Discovery,fund ... phase 1 clinical-trials,program to test new therapies for ... this evening, the grant is among the first,funded ... novel therapies targeted to treat solid tumors, in,collaboration ...
... cancer may have an Achilles, heel, report suggests , , THURSDAY, ... forced metastatic melanoma into remission for the first time, report ... case involves a 79-year-old woman with melanoma tumors in several ... in a gene called KIT, so the patient was enrolled ...
Cached Medicine News:Health News:Donor Dogs Give the Gift of Life 2Health News:Donor Dogs Give the Gift of Life 3Health News:Donor Dogs Give the Gift of Life 4Health News:CoolTouch Introduces CoolBlue Duet(TM) Laser Lipolysis Suction Handpiece 2Health News:Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2
(Date:8/1/2014)... , Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds ... Potassium Nitrate Industry" and "2014 Deep Research Report ... reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice ... causes on July 30. "Sorrento is deeply saddened ... colleague. Our immediate thoughts go to Amar,s family and friends," ... Executive Officer. Mr. Singh joined Sorrento in ...
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Jan. 9, 2012    Lehigh Valley Technologies, Inc. (LVT) ... recently completed inspection by the U.S. Food and ... completed an onsite inspection with no Form 483 ... were no negative observations relating to cGMP (current ...
... Inc.,s ability to craft the pessary balloons that enhance ... commitment to premium quality output and complete mastery of ... Today,s pessaries are precision-manufactured medical devices that provide pelvic ... variety of gynecologic conditions, including prolapse. In years past, ...
Cached Medicine Technology:MedPlast's Pessary Balloon Manufacture Showcases Multi-Function Technical Mastery 2
... The RetCam II is a mobile, self-contained system ... office. It provides state-of-the-art Wide-Field Pediatric Retinal Imaging. ... entire exam and document almost the entire retina with ... RetCam II is our 3 CCD medical grade digital ...
... The new Riata ... physicians even more versatility ... high defibrillation thresholds (DFTs)., ... lead family allows physicians ...
... of use with high software functionality ... guided system for neurosurgery that is ... With a 50% usage rate and ... 500 physicians, VectorVision Cranial is the ...
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
Medicine Products: